Lenalidomide as a Potent Inducer of Graft Versus Leukemia Effect in Patients with Hematologic Malignancies at High Risk of Relapse Post Allogeneic Stem Cell Transplant

Documenti analoghi

• Leflunomide: Is It the Game Changer in Musculoskeletal Chronic Graft Versus Host Disease?
  di: Vijaysekharan, Kalasekhar, et al.
  Pubblicazione: (2018)
• A Limited Sampling Strategy for Therapeutic Drug Monitoring of Mycophenolate Mofetil for Prophylaxis of Acute Graft-Versus-Host Disease in Allogeneic Stem Cell Transplantation
  di: Gota, Vikram, et al.
  Pubblicazione: (2020)
• Real-World Outcomes With Generic Pomalidomide in Relapsed Refractory Multiple Myeloma—Experience From a Tertiary Care Cancer Center
  di: Bondili, Suresh Kumar, et al.
  Pubblicazione: (2021)
• Risk Factors, Pattern and Clinical Outcome of Acute Graft Versus Host Disease in Acute Leukemia Patients Undergoing Allogeneic Stem Cell Transplant
  di: Gupta, Alok, et al.
  Pubblicazione: (2015)
• Chronic Graft Versus Host Disease in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant: Analysis of Risk Factors, Pattern and Long Term Outcome
  di: Punatar, Sachin, et al.
  Pubblicazione: (2015)